Anti Cd 20 Ocrevus denied as non-formulary by Humana?

Humana's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Ocrelizumab as Non-Formulary

A non-formulary denial from Humana means ocrelizumab (Ocrevus) is not included in your specific plan's drug formulary, or it is listed at a tier that requires additional authorization before coverage is granted. Specialty infusion drugs for multiple sclerosis — including ocrelizumab — are frequently placed on restricted formulary tiers by insurers as a cost-management measure. This denial does not reflect a clinical judgment about whether the drug is appropriate; it reflects a coverage-design decision. However, plans are required to provide exceptions processes, and that is the path to coverage.

## Why This Denial Is Appealable

Under ACA §2719 and applicable state insurance law, plans must maintain an exceptions and appeals process for formulary denials. A formulary exception is typically granted when: (1) every formulary alternative for your condition is contraindicated or clinically inappropriate for you specifically; (2) you have tried the formulary alternatives and they have been ineffective or caused significant adverse effects; or (3) there is no formulary alternative for your specific type of MS. Your neurologist's clinical judgment about why ocrelizumab — and not a formulary alternative — is the appropriate agent for your disease profile is the foundation of this appeal.

## Your Federal Appeal Rights

• Internal appeal: ERISA §503 and ACA §2719 entitle you to a full-and-fair internal review of a formulary denial. File within the deadline shown in your denial letter.
• External review: After exhausting internal remedies, an independent external review is available under ACA §2719, generally within approximately four months of final internal denial.
• Expedited track: If a formulary alternative is not clinically viable and a gap in therapy poses health risks, request expedited review; decisions are typically required within 72 hours.

## Documentation to Gather

1. Humana's current formulary — identify which, if any, MS disease-modifying therapies are on formulary for your plan and at what tier. 2. Prescriber letter explaining why each formulary alternative is clinically inadequate for your specific situation — citing your MS classification, disease activity, comorbidities, or prior adverse responses. 3. Prior treatment history — dated records of any formulary or non-formulary agents you have previously tried, with documented outcomes. 4. Diagnosis records — neurologist notes, MRI findings, and clinical documentation establishing your MS diagnosis and classification. 5. Humana's formulary exception criteria — obtain the written exception policy to confirm what clinical grounds Humana will accept.

## Criteria-Mapping Approach

List each formulary alternative Humana's policy identifies for MS in the left column of a table. In the right column, document the specific clinical reason — supported by chart notes — why each alternative is not appropriate for you. If no formulary alternative treats the same type of MS that you have, state that directly with supporting diagnosis documentation. This systematic approach prevents Humana from simply redirecting you to a different formulary agent without engaging with the clinical evidence.

## Next Step

Request Humana's formulary and the written exception criteria before drafting the appeal. Your neurologist's letter is the most critical document and should be drafted after reviewing exactly which alternatives Humana will point to, so each one is addressed directly.